To unveil the role of NORAD in breast cancer, we used LNA GapmeRs and siRNAs targeting both the nuclear and cytoplasmic fractions of NORAD. Two LNA GapmeRs that target different regions of NORAD were tested individually and in combination in the MDA-MB-231 and MDA-MB-468 (Figures S2A–S2C) at final concentrations of 25 and 50 nM. This evidence concerns the gene NORAD and breast cancer.